Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
about
Targeting the Eph System with Peptides and Peptide ConjugatesDiscovery of a Novel Chemotype of Tyrosine Kinase Inhibitors by Fragment-Based Docking and Molecular DynamicsDesign, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathwayHigh Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.Ligand-targeted theranostic nanomedicines against cancerTargeted delivery of paclitaxel to EphA2-expressing cancer cellsDirect cytosolic delivery of polar cargo to cells by spontaneous membrane-translocating peptides.Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting.Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.Secondary nuclear targeting of mesoporous silica nano-particles for cancer-specific drug delivery based on charge inversion.Eph receptors and ephrins: therapeutic opportunities.Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.Design, synthesis, biological evaluation, and 3D-QSAR analysis of podophyllotoxin-dioxazole combination as tubulin targeting anticancer agents.Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2.EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy.A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 ReceptorTherapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.An efficient bioorthogonal strategy using CuAAC click chemistry for radiofluorinations of SNEW peptides and the role of copper depletion.Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.Molecular design and synthesis of self-assembling camptothecin drug amphiphiles.Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures
P2860
Q26799461-8F2055C6-9940-469C-9B70-43E9C3CDE5F5Q27684119-5DA8BDCF-AC38-425A-B8A6-5D344200EEB8Q33848124-C99DB35B-C502-45C3-ABA8-777D4B78E593Q34673530-F362057A-218B-4571-91AC-CA8313DE4270Q35757569-6B95B14C-3BEC-4740-87FB-31176CCAB0CFQ35889278-F74EE1E7-7A71-4FE4-8A0B-1E536BCF1272Q35895637-7814CE4D-E0BF-49B3-B3B1-BBE472850B78Q36511070-5A42D4BA-9133-4A8C-A437-DAE15F20DC1DQ37226280-E4A2D304-445E-44C6-8559-0CB67257B9ADQ37362688-3642CFA7-4DEB-44E0-825D-37DE44D7B248Q37635711-3C457203-0FE7-49F1-8BF7-F900E562E171Q37688492-3C348A3F-161D-48FD-B3F1-0703C5052F8BQ38257853-4ED78B21-3FEC-4F5E-9312-CB15A97CBB68Q38258602-7B3567C0-BB8E-434D-A626-F2FF402BB35EQ38721736-B2D41E52-431F-4FB8-89CC-4BBFF5C29468Q38778869-C1AC1367-DD58-40F1-9289-F6397D59886AQ38952546-0AE4FDD2-47CE-49CC-9D7F-E7831815F3F1Q38990966-CAE74B44-82DE-4D0F-B48A-B29D48D03372Q39081789-6584DAAF-7684-4833-92D6-7C60E5E77940Q39227190-C17D9EAA-B1AC-4519-B40A-806C0C58013DQ39264449-2E26BBC7-D813-4D63-96E5-F2CEFD1734ECQ41388290-9F436B1E-4CC4-408C-9FFC-76B6F7FD8DC2Q41867076-A2B77282-1589-4139-8F76-E66E4CE30A76Q41915374-4F518AB6-3EAD-4803-BC7B-2AEF81BF95DEQ41954025-DAAC4802-E17A-4547-A905-2C2A194F09B9Q44446237-4AF588A8-E630-4A78-9D14-C43D67B64E04Q48226060-7D597C28-EF64-4F11-889D-5DE00711C4FFQ50682565-055DDC3B-ABEE-48BB-BD34-7382F1DB07DEQ51749008-20ED594C-0426-4D37-8A12-E8F3606CD5F0Q57147941-2EF80D8C-A112-43A9-B346-74CE596F7C5A
P2860
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
@en
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
@nl
type
label
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
@en
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
@nl
prefLabel
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
@en
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
@nl
P2093
P2860
P356
P1476
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells
@en
P2093
Elena B Pasquale
John L Stebbins
Maurizio Pellecchia
Mitchell Koolpe
Russell Dahl
Sayantan Mitra
Ziming Zhang
P2860
P304
P356
10.1021/JM201743S
P407
P577
2012-02-27T00:00:00Z